Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -69.14% is 18% below its 5-year average of -58.69%, around the middle of its 5-year range (-107.19%–-35.71%).
9.67% below its 12-month average of -63.05%.
Reported quarterly return on assets; no daily interpolation. Q3 FY2026 (2026-07-31): -17.29%.
RETURN ON ASSETS (ROA)
-69.14%
RETURN ON ASSETS (ROA) AVG TTM
-63.05%
RETURN ON ASSETS (ROA) AVG 3Y
-52.31%
RETURN ON ASSETS (ROA) AVG 5Y
-58.69%
RETURN ON ASSETS (ROA) AVG 10Y
-83.18%
RETURN ON ASSETS (ROA) AVG 15Y
-80.09%
RETURN ON ASSETS (ROA) AVG 20Y
-112.94%
CURRENT VS TTM AVG
-9.67%
CURRENT VS 3Y AVG
-32.18%
CURRENT VS 5Y AVG
-17.81%
CURRENT VS 10Y AVG
+16.88%
CURRENT VS 15Y AVG
+13.67%
CURRENT VS 20Y AVG
+38.78%
SECTOR MEDIAN · HEALTHCARE
-26.34%
median of 496 covered companies
CURRENT VS SECTOR MEDIAN
-162.44%
vs the sector median at left
Anixa Biosciences, Inc.
Market Cap
$100.37M
Return on Assets (ROA)
-69.14%
TTM Avg
-63.05%
3Y Avg
-52.31%
5Y Avg
-58.69%
Market Cap
$99.24M
Return on Assets (ROA)
-65.25%
TTM Avg
-70.13%
3Y Avg
-63.89%
5Y Avg
-46.24%
Market Cap
$102.43M
Return on Assets (ROA)
7.36%
TTM Avg
-1.10%
3Y Avg
-3.18%
5Y Avg
2.66%
Market Cap
$104.07M
Return on Assets (ROA)
-33.85%
TTM Avg
-28.41%
3Y Avg
-17.06%
5Y Avg
-12.28%
Market Cap
$106.23M
Return on Assets (ROA)
-16.87%
TTM Avg
-6.13%
3Y Avg
-6.48%
5Y Avg
-5.59%
Market Cap
$93.99M
Return on Assets (ROA)
-88.24%
TTM Avg
-139.34%
3Y Avg
-100.15%
5Y Avg
-71.92%
Market Cap
$108.39M
Return on Assets (ROA)
-80.25%
TTM Avg
-36.24%
3Y Avg
-78.62%
5Y Avg
-77.58%
Market Cap
$91.68M
Return on Assets (ROA)
-30.70%
TTM Avg
-50.88%
3Y Avg
-51.94%
5Y Avg
-48.05%
Market Cap
$91.33M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anixa Biosciences, Inc. (ANIX) | $100.37M | -69.14% | -63.05% | -52.31% | -58.69% |
| Korro Bio, Inc. (KRRO)vs › | $99.24M | -65.25% | -70.13% | -63.89% | -46.24% |
| The Joint Corp. (JYNT)vs › | $102.43M | 7.36% | -1.10% | -3.18% | 2.66% |
| Definitive Healthcare Corp. (DH)vs › | $104.07M | -33.85% | -28.41% | -17.06% | -12.28% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.23M | -16.87% | -6.13% | -6.48% | -5.59% |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | -88.24% | -139.34% | -100.15% | -71.92% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.39M | -80.25% | -36.24% | -78.62% | -77.58% |
| Equillium, Inc. (EQ)vs › | $91.68M | -30.70% | -50.88% | -51.94% | -48.05% |
| electroCore, Inc. (ECOR)vs › | $91.33M | -86.56% | -66.44% | -84.84% | -75.69% |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -14.14% | -26.48% | -30.34% | -26.58% |
ROA
-69.1%
ROE
-72.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-10-31 | -67.95% |
| 2024-10-31 | -58.14% |
| 2023-10-31 | -38.44% |
| 2022-10-31 | -44.70% |
| 2021-10-31 | -35.71% |
| 2020-10-31 | -107.19% |
| 2019-10-31 | -185.06% |
| 2018-10-31 | -217.04% |
| 2017-10-31 | -56.84% |
| 2016-10-31 | -89.13% |
| 2015-10-31 | -14.77% |
| 2014-10-31 | -106.08% |
| 2013-10-31 | -185.31% |
| 2012-10-31 | -75.13% |
| 2011-10-31 | -85.34% |
| 2010-10-31 | -51.51% |
| 2009-10-31 | -167.43% |
| 2008-10-31 | -77.64% |
| 2007-10-31 | -291.86% |
| 2006-10-31 | -407.85% |
| 2005-10-31 | -303.58% |
| 2004-10-31 | -145.10% |
| 2003-10-31 | -133.64% |
| 2002-10-31 | -120.27% |
| 2001-10-31 | -54.43% |
| 2000-10-31 | -72.00% |
| 1999-10-31 | -104.94% |
| 1998-10-31 | -53.38% |
| 1997-10-31 | -29.00% |
| 1996-10-31 | -21.86% |
